Results 151 to 160 of about 146,874 (392)

A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. [PDF]

, 2015
Although recent methods for the engineering of antibody-drug conjugates (ADCs) have gone some way to addressing the challenging issues of ADC construction, significant hurdles still remain.
Caddick, S, Chester, KA, Chudasama, V, Maruani, A, Miranda, E, Smith, ME   +5 more
core   +1 more source

Natural Products Targeting the EGFR/HER2 Axis in Tumorigenesis: Interpretation of Molecular Mechanisms and Recent Insights Into Synergistic Strategies for Cancer Therapy

Food Frontiers, EarlyView.
Schematic overview illustrating the anticancer mechanisms of selected natural products (resveratrol, quercetin, berberine) targeting EGFR and HER2 signaling pathways in tumor cells. These compounds inhibit receptor activation and downstream oncogenic cascades, including PI3K/Akt/mTOR, MAPK/ERK, and STAT3 pathways.
Iman Ramli, Anna Maria Posadino, Roberta Giordo, Antonio Barberis, Ylenia Spissu, Redouane Lemoui, William N. Setzer, Javad Sharifi‐Rad, Gianfranco Pintus   +8 more
wiley   +1 more source

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

Breast Cancer Research, 2019
Background Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology.
Sònia Palomeras, Ángel Diaz-Lagares, Gemma Viñas, Fernando Setien, Humberto J. Ferreira, Glòria Oliveras, Ana B. Crujeiras, Alejandro Hernández, David H. Lum, Alana L. Welm, Manel Esteller, Teresa Puig   +11 more
doaj   +1 more source

Cannabinoid receptor CB2 drives HER2 pro-oncogenic signaling in breast cancer [PDF]

, 2015
Pharmacological activation of cannabinoid receptors elicits antitumoral responses in different models of cancer. However, the biological role of these receptors in tumor physio-pathology is still unknown.
Alkatout, Ibrahim, Andradas, Clara, Arnold, Norbert, Artola, Marta, Bauer, Maret, Blasco-Benito, Sandra, Bronsert, Peter, Caffarel, María M., Canela, Enric I., Fernández-Piqueras, José, Flores, Juana M., García-Taboada, Elena, Guzmán, Manuel, Hamann, Sigrid, Klapper, Wolfram, Martín-Villar, Ester, McCormick, Peter J., Megías, Diego, Moreno, Estefanía, Moreno-Bueno, Gema, Ortega-Gutiérrez, Silvia, Pérez-Gómez, Eduardo, Pérez-Martínez, Manuel, Quintanilla, Miguel, Röcken, Christoph, Soriano, Joaquim, Staebler, Annette, Stickeler, Elmar, Sánchez, Cristina, Villa-Morales, María, Vázquez-Villa, Henar, Wenners, Antonia   +31 more
core   +1 more source

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

Journal of Clinical Oncology, 2019
PURPOSE The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the treatment human epidermal growth factor receptor 2–positive stage II to III breast cancer.
S. Hurvitz, Miguel Martín, K. Jung, Chiun-Sheng Huang, N. Harbeck, V. Valero, D. Stroyakovskiy, H. Wildiers, M. Campone, J. Boileau, Peter A. Fasching, K. Afenjar, G. Spera, V. López-Valverde, Chunyan Song, P. Trask, T. Boulet, J. Sparano, W. Symmans, Alastair M Thompson, D. Slamon   +20 more
semanticscholar   +1 more source

Herceptin™ (trastuzumab) in patients who overexpress Her-2 and have failed multiple chemotherapy regimens for advanced breast cancer: a pragmatic study [PDF]

, 2000
Gunnar Westman
openalex   +1 more source

A Non-Covalent Antibody Complex for the Delivery of anti-cancer drugs [PDF]

, 2019
Antibody drug conjugates (ADCs), which are obtained by coupling a potent cytotoxic agent to a monoclonal antibody (mAb), are traditionally bound in a random way to lysine or cysteine residues, with the final product's heterogeneity having an important ...
Grigoletto, Antonella, Maso, Katia, Monia Montagner, Isabella, Pasut, Gianfranco, Rosato, Antonio, Schiavon, Oddone   +5 more
core   +1 more source

Anti‐Her2 therapy patterns in metastatic breast cancer—Real‐world data suggest undertreatment

International Journal of Cancer, EarlyView.
What's New? Although human epidermal growth factor 2‐positive (HER2+) breast cancer is an aggressive malignancy, significant survival benefits are possible with targeted anti‐HER2 therapies. Whether these therapies are used as recommended, however, is unknown. Here, the authors investigated data from population‐based registries in Norway to assess anti‐
Kathrine F. Vandraas, Sarah Hjorth, Cassia B. Trewin‐Nybråten, Giske Ursin, Edoardo Botteri, Bettina Kulle Andreassen, Kristin V. Reinertsen, Egil S. Blix, Bjørn Naume, Nathalie C. Støer   +9 more
wiley   +1 more source

Docetaxel und Trastuzumab: Eine klinisch bedeutsame Kombination [PDF]

, 2000
Gottfried E. Konecny, Mark D. Pegram, Dennis J. Slamon   +2 more
openalex   +1 more source

Evaluating distant recurrence‐free survival and location of metastasis in HER2+ breast cancer by ER status

International Journal of Cancer, EarlyView.
What's New? The prognostic significance of the presence or absence of human epidermal growth factor receptor 2 (HER2) and estrogen receptor (ER) in breast cancer is well‐established. However, the relationship of HER2 and ER with distant disease recurrence and metastasis location is less well understood.
Damien Kaukonen, Alexander Ploner, Erwei Zeng, Jenny Bergqvist, Kamila Czene   +4 more
wiley   +1 more source